Emergent Biosolutions EBS Payments to notes receivables
Payments to notes receivables at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireNotesReceivable.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's payments to notes receivables.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's payments to notes receivables?
- Emergent Biosolutions (EBS) reported payments to notes receivables of $0 in Q1 2026.
- How has Emergent Biosolutions's payments to notes receivables changed year-over-year?
- Emergent Biosolutions's payments to notes receivables decreased by 100.0% year-over-year, from $5M to $0.
- What does payments to notes receivables mean?
- Measures the cash used to purchase debt instruments or notes receivable from third parties as part of an investment or financing strategy. This activity reflects the company's deployment of excess liquidity into interest-bearing assets. It is a key indicator of how the firm manages its cash reserves beyond core operations.